PMID- 32175118
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231113
IS  - 2078-6891 (Print)
IS  - 2219-679X (Electronic)
IS  - 2078-6891 (Linking)
VI  - 11
IP  - 1
DP  - 2020 Feb
TI  - The emerging role of proton therapy for esophagus cancer.
PG  - 144-156
LID - 10.21037/jgo.2019.11.04 [doi]
AB  - Chemoradiotherapy (CRT) plays an essential role in the treatment of esophageal 
      cancer as either curative or neoadjuvant therapy. When delivered with 
      conventional photon-based techniques, multiple adjacent organs at risk including 
      the heart, lungs, kidneys, liver, stomach, and bowel, receive considerable 
      radiation dose which may contribute to acute and late adverse events (AEs). 
      Proton beam therapy (PBT) offers a reduction in radiation exposure to these 
      organs and potentially an improvement in the therapeutic ratio. Herein we discuss 
      the emerging role of PBT for esophageal cancer, including rationale, treatment 
      planning, early dosimetric and clinical comparisons of PBT with photon-based 
      techniques, ongoing prospective trials, and potential areas of opportunity for 
      the incorporation of PBT with the goal of improving outcomes for patients with 
      esophageal cancer.
CI  - 2020 Journal of Gastrointestinal Oncology. All rights reserved.
FAU - Jethwa, Krishan R
AU  - Jethwa KR
AD  - Department of Therapeutic Radiology, Yale University School of Medicine, New 
      Haven, CT, USA.
FAU - Haddock, Michael G
AU  - Haddock MG
AD  - Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
FAU - Tryggestad, Erik J
AU  - Tryggestad EJ
AD  - Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
FAU - Hallemeier, Christopher L
AU  - Hallemeier CL
AD  - Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - J Gastrointest Oncol
JT  - Journal of gastrointestinal oncology
JID - 101557751
PMC - PMC7052753
OTO - NOTNLM
OT  - Esophagus cancer
OT  - chemoradiation
OT  - proton therapy
COIS- Conflicts of Interest: The authors have no conflicts of interest to declare.
EDAT- 2020/03/17 06:00
MHDA- 2020/03/17 06:01
PMCR- 2020/02/01
CRDT- 2020/03/17 06:00
PHST- 2020/03/17 06:00 [entrez]
PHST- 2020/03/17 06:00 [pubmed]
PHST- 2020/03/17 06:01 [medline]
PHST- 2020/02/01 00:00 [pmc-release]
AID - jgo-11-01-144 [pii]
AID - 10.21037/jgo.2019.11.04 [doi]
PST - ppublish
SO  - J Gastrointest Oncol. 2020 Feb;11(1):144-156. doi: 10.21037/jgo.2019.11.04.